Skip to main content
OpenTrials
Completed

NCT Number: NCT05844787

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

The primary study objective is to establish the safety and tolerability of MT101-5 after a single and multiple dose administrations in healthy volunteers. The safety and overall tolerability of MT101-5 will be evaluated based on:

* Incidence of Dose Limiting Toxicities (DLTs) * Incidence of Treatment-Emergent Adverse Events (TEAEs). * Incidence of withdrawals due to Adverse Events (AEs). * Change/shifts in laboratory values. Change in vital signs. * Change in Electrocardiogram (ECG) parameters. * Changes in physical examination findings

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Frontage Clinical Services, 1nc.

Secaucus, New Jersey, 07094, United States

About this study

SAD Phase including Food Interaction:

Subjects will be assigned to one of up to five MT101-5 treatment cohorts and will be randomly assigned 6:2 within their cohort to receive MT101-5 or placebo. On Day 1, following an overnight fast of at least 10 hours, the randomly assigned dose of MT101-5 or placebo will be administered as oral tablet in a fasting state with 240 mL (i.e., 8 fluid ounces) of water. Additional water is permitted ad lib except for the period 1 hour before to 1 hour after administration of the drug product. No food is allowed for at least 4 hours after the dose. Subjects should receive standardized meals scheduled at the same time throughout the study.

For the Food Interaction phase, on Day 1 following an overnight fast of at least 10 hours, the study subjects should start their standardized high-fat breakfast meal 30 minutes before administration of the drug product. Trial subjects should eat this meal in 30 minutes or less. Subjects will be administered MT101-5 or placebo as an oral tablet 30 minutes after start of intake of a standardized high-fat breakfast with 240 mL (8 fluid ounces) of water. Additional water is allowed ad lib except for 1 hour before and 1 hour after drug administration. No food is allowed for at least 4 hours after the dose.

MAD Phase:

Subjects will be randomly assigned 6:2 to receive MT101-5 or placebo once daily for 7 days. On Day 1, following an overnight fast of at least 10 hours, the randomly assigned dose of MT101-5 or placebo will be administered as oral tablet in a fasting state with 240 mL (i.e., 8 fluid ounces) of water. Additional water is permitted ad lib except for the period 1 hour before to 1 hour after administration of the drug product. No food is allowed for at least 4 hours after the dose. Subjects should receive standardized meals scheduled at the same time throughout the study. The same will be followed for days 2-7.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects will be eligible for enrollment in the study only if they meet ALL of the following criteria:

  • Age:
  • SAD & Food Interaction: Healthy male and female subjects, 18 to 45 years of age, inclusive.
  • MAD: Elderly healthy male and female subjects ≥ 65 years of age
  • BMI:
  • SAD & Food Interaction: The subject has a body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive, and weighs at least 50 kg.
  • MAD: The subject has a body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, and weighs at least 50 kg.
  • The subject is in good health and has no medical condition of clinical significance or that may impact the outcome of the study, as determined by the investigator (as determined by medical history, physical examination, 12-lead electrocardiogram [ECG], vital signs, and clinical laboratory results at screening).
  • The subject is able to understand the nature of the study and any potential hazards associated with participating in it.
  • The subject is able to communicate satisfactorily with the investigator and to participate in, and comply with, the requirements of the study.
  • The subject is willing to provide written informed consent to participate in the study after reading the informed consent form and the information provided and has had the opportunity to discuss the study with the investigator or designee.
  • Negative pregnancy test for female subjects of childbearing potential. Women of childbearing potential (WOCBP) and Women of non-childbearing potential are eligible to participate. Both women of childbearing potential and women of non-childbearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study (and for 90 days after taking the last dose of MT101-5).

Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (e.g., diaphragm, cervical cap, male condom, and female condom and spermicidal foam, sponges, and film) (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile at least three months before screening (confirmed by study doctor) or 2 years post-menopausal (patient reported) confirmed with FSH/estradiol levels at screening. All male subjects/partners must agree to consistently and correctly use a condom for the duration of the study and for 90 days after taking the study drug. In addition, subjects may not donate sperm for the duration of the study and for 90 days after taking study drug.

Exclusion criteria

Subjects will be eligible for enrollment in the study only if they meet NONE of the following criteria:

  • The subject has a history of severe allergic or anaphylactic reactions.
  • The subject has a known allergy or hypersensitivity to any component of the formulation.
  • The subject has a medical history or current evidence of any clinically significant (as determined by the investigator) cardiac, endocrine (including diabetes), hematologic, hepatobiliary (abnormal alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transpeptidase [GGT], or total bilirubin), immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal condition, or other major disease.
  • The subject has a history of any malignant disease.
  • The subject has a history of more than one herpes zoster episode or multimetameric herpes zoster.
  • The subject has a history of an opportunistic infection (e.g. cytomegalovirus, pneumocystis carinii, aspergillosis, clostridium difficile).
  • The subject has a history of or ongoing chronic or recurrent infectious disease (e.g. infected indwelling prosthesis, osteomyelitis, chronic sinusitis).
  • The subject has had major trauma or surgery in the 2 months before screening or at any time between screening and check-in.
  • The subject has had an acute infection within 2 weeks before screening or at any time between screening and check-in including, but not limited to, history, signs, or symptoms of a common cold (e.g., mild rhinorrhea), untreated oral/dental abnormalities (e.g. untreated dental caries as determined by examination of the mouth), or untreated disruption of the skin.
  • The subject has clinically significant abnormal ECG findings at screening, check-in visits, or predose, as determined by the Investigator.
  • The subject has a supine blood pressure measurement outside the ranges of the below at screening, check-in, or predose. Note: If either value is out of the range, blood pressure measurements may be repeated in the supine position at intervals of 5 to 10 minutes up to 3 times. If the mean systolic or diastolic measurement continues to exceed the stated limits, the subject will be excluded.
  • SAD: Ranges 90 to 140 mm Hg systolic or 45 to 90 mm Hg diastolic (measured after a rest of at least 5 minutes)
  • MAD: Ranges 90 to 150 mm Hg systolic or 45 to 95 mm Hg diastolic (measured after a rest of at least 5 minutes)
  • The subject has a pulse of fewer than 45 beats per minute (bpm) or greater than 100 bpm (measured after a rest of at least 5 minutes) at screening, check-in, or predose.
  • The subject tests positive for tuberculosis (TB) at screening by the QuantiFERON-TB Gold Test, or has a history of latent, inadequately treated, or active TB.
  • The subject has a known history of, or a positive test result for, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) types 1 or 2 at screening.
  • The subject has used prescription or over-the-counter (OTC) medication (other than ≤2 g/day paracetamol [acetaminophen] or ≤800 mg/day ibuprofen), vitamins, or herbal remedies, within 2 weeks or 5 half-lives before study drug administration, whichever is longer.
  • The subject has participated in another clinical study of a new investigational drug or has received an investigational drug within the 3 months or 5 half-lives (if available) before study drug administration, whichever is longer.
  • The subject has had a loss of more than 400 mL of blood (e.g. a blood donation) within 2 months before study drug administration, or has received any blood, plasma, or platelet transfusions within 3 months before check-in, or plans to donate blood during the study or within 3 months after the study.
  • The subject has a history of alcohol abuse (defined as an alcohol intake more than 21 units per week) or a history of drug abuse within the 6 months before study drug administration, or a history of substance abuse deemed significant by the investigator. A unit of alcohol is defined as 240 mL of beer, 120 mL of wine, or 1 single shot of spirits. The subject will be required to abstain from alcohol consumption 48 hours prior to screening or check-in.
  • Current smokers and those who have smoked within the last 2 years. This includes the use of cigarettes, e-cigarettes, and nicotine replacement products.
  • The subject has a positive test for alcohol or drugs of abuse (barbiturates, methamphetamine, benzodiazepines, morphine/opiates, phencyclidine (PCP), amphetamines, tetrahydrocannabinol (THC), methylenedioxymethamphetamine (MDMA), cocaine, methadone, and cotinine) at screening or check-in.
  • The subject is unable to participate in, or successfully complete, the study, in the opinion of their general practitioner or the investigator, because the subject is any of the following:
  • mentally or legally incapacitated, or unable to give consent for any reason
  • in custody due to an administrative or a legal decision, or under tutelage, or being admitted to a sanitarium or social institution
  • unable to be contacted in case of emergency
  • unlikely to cooperate or comply with the clinical study protocol or is unsuitable for any other reason

Treatment and study plan

MT101-5

Drug

Tablet

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLTs)

    Time frame: Day 1 through 7 days after the last study drug administration

    Any clinically significant adverse event (AE)/serious adverse event (SAE) or clinically significant laboratory abnormality which is classified as > Grade 2 (according to the National Cancer Institute Common Terminology Criteria for Adverse Events [CTCAE] version 5.0), where applicable, deemed by the investigator as at least "possibly, probably or definitely related" to the drug but unrelated to concurrent illness, or concomitant medications.

  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Day 1 through 7 days after the last study drug administration

    An adverse event (AE) is defined as any unfavorable or unintended sign, symptom, or disease that occurs or is reported by the patient to have occurred, or a worsening of a pre-existing condition. An adverse event may or may not be related to the study treatment.

  3. Incidence of withdrawals due to Adverse Events (AEs)

    Time frame: Day 1 through 7 days after the last study drug administration

    Incidence of withdrawals due to Adverse Events (AEs) defined above

  4. Change in complete blood count test

    Time frame: Change from baseline to day 7 after the first study drug administration

  5. Change in comprehensive metabolic panel test

    Time frame: Change from baseline to day 7 after the first study drug administration

  6. Change in urinalysis test

    Time frame: Change from baseline to day 7 after the first study drug administration

  7. Change in pregnancy test

    Time frame: Change from baseline to day 7 after the first study drug administration

  8. Change of blood pressure (both systolic and diastolic blood pressures)

    Time frame: Change from pre-dose to 96 hours after last study drug administration

  9. Change of blood pressure (both systolic and diastolic blood pressures)

    Time frame: Change from pre-dose to day 7 after the last study drug administration

  10. Change of pulse

    Time frame: Change from pre-dose to 96 hours after last study drug administration

  11. Change of pulse

    Time frame: Change from pre-dose to day 7 after the last study drug administration

  12. Change of temperature

    Time frame: Change from pre-dose to 96 hours after last study drug administration

  13. Change of temperature

    Time frame: Change from pre-dose to day 7 after the last study drug administration

  14. Change of respiratory rate

    Time frame: Change from pre-dose to 96 hours after last study drug administration

  15. Change of respiratory rate

    Time frame: Change from pre-dose to day 7 after the last study drug administration

  16. ECG ventricular rate (beats per minute)

    Time frame: At pre-dose

  17. ECG ventricular rate (beats per minute)

    Time frame: 96 hours after study drug administration

  18. ECG ventricular rate (beats per minute)

    Time frame: On day 7 after the last study drug administration

  19. PR interval (msec)

    Time frame: At pre-dose

  20. PR interval (msec)

    Time frame: 96 hours after study drug administration

  21. PR interval (msec)

    Time frame: On day 7 after the last study drug administration

  22. QRS interval (msec)

    Time frame: At pre-dose

  23. QRS interval (msec)

    Time frame: 96 hours after study drug administration

  24. QRS interval (msec)

    Time frame: On day 7 after the last study drug administration

  25. QT interval (msec)

    Time frame: At pre-dose

  26. QT interval (msec)

    Time frame: 96 hours after study drug administration

  27. QT interval (msec)

    Time frame: On day 7 after the last study drug administration

  28. QTc interval (msec)

    Time frame: At pre-dose

  29. QTc interval (msec)

    Time frame: 96 hours after study drug administration

  30. QTc interval (msec)

    Time frame: On day 7 after the last study drug administration

  31. Maximum observed plasma drug concentration (Cmax)

    Time frame: 0-96 hours

  32. Apparent terminal elimination half-life (t1/2)

    Time frame: 0-96 hours

  33. Time to maximum observed plasma drug concentration (Tmax)

    Time frame: 0-96 hours

  34. Area under the plasma drug concentration-time curve (AUC)

    Time frame: 0-96 hours

  35. Percentage of AUC0-∞ extrapolated from Tlast to infinity (AUCext)

    Time frame: 0-96 hours

  36. Apparent plasma clearance (CL/F)

    Time frame: 0-96 hours

  37. Apparent Volume of distribution (Vz/F)

    Time frame: 0-96 hours

Sponsors and collaborators

Lead sponsor

Mthera Pharma Co., Ltd.

Industry

Collaborators

  • Amarex Clinical Research

Registry information

Official study title

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
May 6, 2023
Registry last updated
May 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.